Abstract:Microglia are the resident immune cells in the spinal cord and brain. Mounting evidence suggests that activation of microglia plays an important role in the pathogenesis of chronic pain, including chronic orofacial pain. In particular, microglia contribute to the transition from acute pain to chronic pain, as inhibition of microglial signaling reduces pathologic pain after inflammation, nerve injury, and cancer but not baseline pain. As compared with inflammation, nerve injury induces much more robust morphologic activation of microglia, termed microgliosis, as shown by increased expression of microglial markers, such as CD11b and IBA1. However, microglial signaling inhibitors effectively reduce inflammatory pain and neuropathic pain, arguing against the importance of morphologic activation of microglia in chronic pain sensitization. Importantly, microglia enhance pain states via secretion of proinflammatory and pronociceptive mediators, such as tumor necrosis factor α, interleukins 1β and 18, and brain-derived growth factor. Mechanistically, these mediators have been shown to enhance excitatory synaptic transmission and suppress inhibitory synaptic transmission in the pain circuits. While early studies suggested a predominant role of microglia in the induction of chronic pain, further studies have supported a role of microglia in the maintenance of chronic pain. Intriguingly, recent studies show male-dominant microglial signaling in some neuropathic pain and inflammatory pain states, although both sexes show identical morphologic activation of microglia after nerve injury. In this critical review, we provide evidence to show that caspase 6—a secreted protease that is expressed in primary afferent axonal terminals surrounding microglia—is a robust activator of microglia and induces profound release of tumor necrosis factor α from microglia via activation of p38 MAP kinase. The authors also show that microglial caspase 6/p38 signaling is male dominant in some inflammatory and neuropathic pain conditions. Finally, the authors discuss the relevance of microglial signaling in chronic trigeminal and orofacial pain.

Activation and regulation of caspase-6 and its role in neurodegenerative diseases.

The Regulatory Mechanism of the Caspase 6 Pro-Domain Revealed by Crystal Structure and Biochemical Assays

Inhibitory Mechanism of Caspase-6 Phosphorylation Revealed by Crystal Structures, Molecular Dynamics Simulations, and Biochemical Assays*

CXCL10-induced cell death in neurons: role of calcium dysregulation.

Alternatively Spliced Caspase-6B Isoform Inhibits the Activation of Caspase-6A

Caspase-6 is a Key Regulator of Cross-Talk Signal Way in PANoptosis in Cancer

A Caspase Cascade Regulating Developmental Axon Degeneration.

Caspase-6 Promotes Activation of the Caspase-11-nlrp3 Inflammasome During Gram-Negative Bacterial Infections.

Caspase-6 Is a Key Regulator of Innate Immunity, Inflammasome Activation, and Host Defense

Old, new and emerging functions of caspases

Caspase-8 in inflammatory diseases: a potential therapeutic target

The role of NLRP6 in the development and progression of neurological diseases

Human Caspases: Activation, Specificity, and Regulation

Microglial Signaling in Chronic Pain with a Special Focus on Caspase 6, P38 MAP Kinase, and Sex Dependence

Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation.

Identification of Caspase-6 As a New Regulator of Alternatively Activated Macrophages*

The Molecular Mechanism of Caspase Activation and Regulation

Newly Identified Function of Caspase-6 in ZBP1-mediated Innate Immune Responses, NLRP3 Inflammasome Activation, PANoptosis, and Host Defense

Targeting CARD6 attenuates spinal cord injury (SCI) in mice through inhibiting apoptosis, inflammation and oxidative stress associated ROS production

Caspase 6 promotes innate immune activation by functional crosstalk between RIPK1-IκBα axis in liver inflammation

Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β